CIM LLC’s Stoke Therapeutics STOK Stock Holding History

CIM LLC’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$476K	Buy	14,556 +328	+2%	+$10.5K	0.06%	140
2026 Q1	$463K	Buy	+14,228	New	+$467K	0.07%	123

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIM LLC's STOK Position: Q2 2026 in Review

CIM LLC increased its Stoke Therapeutics (STOK) stake by 2.3% in Q2 2026, buying an estimated $10.5K and bringing the position to 14,556 shares worth $476K. The position accounts for 0.06% of the portfolio, ranked #140.

CIM LLC first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

CIM LLC held 14,556 shares of Stoke Therapeutics worth $476K as of Q2 2026.
CIM LLC bought 328 Stoke Therapeutics shares in Q2 2026, an estimated $10.5K.
Stoke Therapeutics made up 0.06% of CIM LLC's portfolio in Q2 2026, its #140 holding.
CIM LLC first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on CIM LLC's 13F filing for Q2 2026, filed 13 Aug 2026.